marketshareAI
Theme

Cambridge Cognition Holdings

COGHealthcare
38.00GBX
0.00%
Market Cap
17.47M
Volume
131
0% of avg
P/E Ratio
14.45
EPS (TTM)
2.63
Beta
0.53
Day Range
0.00p - 0.00p
52 Week Range
0.00p38.00p47.00p
38.00p

Upcoming Events

31 December 2025
Board changes: Debra Leeves and Richard Bungay to leave the Board
2026 AGM
Dr. Steven Powell to step down as Chair
Q2 2026
Next AGM where Dr Steven Powell will step down as Chair
January 2027
First Phase 3 trial completion
High Impact Event
January 2029
Second Phase 3 trial completion
High Impact Event
2031
Contract end date
High Impact Event
COG
NEUTRAL

Cambridge Cognition Announces Holding Change

The healthcare technology company has announced a change in shareholding, with Octopus Investments Limited reducing its stake.

COG
NEUTRAL

Cambridge Cognition Holdings Plc Announces Holding(s) in Company

The healthcare technology company has announced a change in shareholding.

COG
NEUTRAL

Cambridge Cognition Holdings Plc Announces Change in Voting Rights

The healthcare technology company has announced a change in its major shareholder's voting rights.

COG
NEUTRAL

Cambridge Cognition Holdings Announces Director Dealings

The healthcare technology company has announced changes to its major shareholders.

COG
NEUTRAL

Cambridge Cognition Provides Investor Presentation Update

The brain health software group announces an upcoming investor presentation, providing an opportunity for existing and potential shareholders to learn more about the company.

COG
GOOD

Cambridge Cognition Raises £1.12m in Premium Placing

The brain health software group raises £1.12 million through a placing and subscription, with the new shares issued at a premium to the previous closing price.

COG
NEUTRAL

Cambridge Cognition Announces Changes to Board and Management

The healthcare software group announces changes to its board and executive leadership team, including new appointments and departures.

COG
BAD

Cambridge Cognition Reports Mixed H1 2025 Results with Revenue Decline but Strong Order Book Growth

The brain health software group reported a revenue decline and widening losses in H1 2025, despite growth in new sales orders and order book. A proposed equity raise aims to strengthen working capital.

COG
NEUTRAL

Cambridge Cognition Announces Monument Therapeutics Partnership with FNIH

The brain health software group announces its investment, Monument Therapeutics, has partnered with the FNIH to evaluate a novel treatment for cognitive impairment associated with schizophrenia.

COG
NEUTRAL

Cambridge Cognition Launches New Speaker Identification Solution

The healthcare technology company has launched a new speaker identification solution to help tackle duplicate participant enrolment in clinical trials.